BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ChamberMaster//Event Calendar 2.0//EN METHOD:PUBLISH X-PUBLISHED-TTL:P3D REFRESH-INTERVAL:P3D CALSCALE:GREGORIAN BEGIN:VEVENT DTSTART:20181010T230000Z DTEND:20181011T003000Z X-MICROSOFT-CDO-ALLDAYEVENT:FALSE SUMMARY:Challenges of Antibiotic Drug Development DESCRIPTION:SCIENCE AS A WAY OF UNDERSTANDING. Dr. Steve Rittenhouse explains how the ability of bacteria to rapidly evolve resistance makes the development of new antibiotics a challenging task indeed.\n\n\nDr. Steve Rittenhouse\, our neighbor at the Collegeville facility of GlaxoSmithKline\, is Director of Microbiology in the Antibacterial Discovery Performance Unit. Steve received his Ph.D. in Pharmacology from Temple University\, an MA in Biology from Villanova University\, and a BS in Biology from Ursinus College. He joined SmithKline Beecham\, a legacy company of GSK\, in 1990\, at a time when our rapid understanding of bacterial genomics was believed to be on the verge of revolutionizing antibacterial drug discovery.\n\nAn expert in the in vitro characterization of antimicrobial agents and preclinical models of bacterial infection\, Steve has authored over 100 publications\, presentations and abstracts related to antibiotic drug discovery. He has led multiple antibacterial discovery programs at GSK that have progressed candidates to clinical development\, including Retapamulin\, which was the first pleuromutilin antibacterial approved for clinical use. He is the Industry Representative for the Eastern PA Branch of the American Society for Microbiology and has been an active member for more than 25 years. X-ALT-DESC;FMTTYPE=text/html:
SCIENCE AS A WAY OF UNDERSTANDING. Dr. Steve Rittenhouse explains how the ability of bacteria to rapidly evolve resistance makes the development of new antibiotics a challenging task indeed.
\n\n
\n

Dr. Steve Rittenhouse\, our neighbor at the \;Collegeville facility of GlaxoSmithKline\, is Director of Microbiology in the Antibacterial Discovery Performance Unit. Steve received his Ph.D. in Pharmacology from Temple University\, an MA in Biology from Villanova University\, and a BS in Biology from Ursinus College. He joined SmithKline Beecham\, a legacy company of GSK\, in 1990\, at a time when our rapid understanding of bacterial genomics was believed to be on the verge of revolutionizing antibacterial drug discovery.

\n\n

An expert in the \;in vitro \;characterization of antimicrobial agents and preclinical models of bacterial infection\, Steve has authored over 100 publications\, presentations and abstracts related to antibiotic drug discovery. He has led multiple antibacterial discovery programs at GSK that have progressed candidates to clinical development\, including Retapamulin\, which was the first pleuromutilin antibacterial approved for clinical use. He is the Industry Representative for the Eastern PA Branch of the American Society for Microbiology and has been an active member for more than 25 years.

\n
\n LOCATION:Olin Auditorium Ursinus College 601 East Main Street Collegeville\, PA 19426 UID:e.2183.851705 SEQUENCE:3 DTSTAMP:20260409T083926Z URL:https://business.tricountyareachamber.com/events/details/challenges-of-antibiotic-drug-development-851705 END:VEVENT END:VCALENDAR